Axsome Eyes Phase 3 Trial Milestones for Sleep Disorder Drugs
Axsome detailed anticipated milestones for investigational drugs for narcolepsy and EDS associated with shift work disorder.
Source: sleepreviewmag.com
Stay updated with breaking news from Pipeline Anticipated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Axsome detailed anticipated milestones for investigational drugs for narcolepsy and EDS associated with shift work disorder.
Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million,...